#125 - CLINICAL AND TECHNICAL SUCCESS OF EUS-GUIDED ANTEROGRADE DRAINAGE OF OBSTRUCTED BILIARY OR PANCREATIC DUCT: A SINGLE-CENTER EXPERIENCE

https://doi.org/10.46613/congastro2023-125

Robles C1, Alcivar J1, Puga M1, Egas M1, Baquerizo J1, Arevalo M1, Cunto D1, Del Valle R1, Alvarado H1, Pitanga H1

1Instituto Ecuatoriano de Enfermedades Digestivas (IECED), Guayaquil, Ecuador

BACKGROUND: The first-line treatment for obstructed biliary or pancreatic ducts is endoscopic retrograde cholangiopancreatography (ERCP); 10-15% have failed access due to the inability to cannulate the papilla. Endoscopic ultrasound-guided biliary drainage (EUS-BD) or pancreatic duct drainage (EUS-PDD) are direct real-time access to the ducts. They are alternatives to high morbimortality percutaneous drainage.

AIM: To assess anterograde's clinical and technical success in non-neoplastic biliary and pancreatic duct drainage.

METHODS: Retrospective analysis (Jan/2021-Oct/2022). The endpoints were clinical and technical success, adverse events, re-stenosis, and reintervention.

RESULTS: Twenty patients were included (15/20 EUS-BD, 5/20 EUS-PDD). EUS-BD: inability to cannulate the papilla was due to stenosis secondary to 6/15 laparoscopic cholecystectomy, 7/15 conventional cholecystectomy, 1/15 gallbladder neoplasia, 1/15 Y-Roux. In 4/15 a previous attempt was performed: 1/4 balloon dilation, 1/4 percutaneous transhepatic biliary drainage and 2/4 stenting. Anterograde drainage was performed on 7/15 using a single pigtail, 5/15 double pigtail and 3/15 lumen-apposing metal stent (LAMS). Stomach puncture was the preferred approach site (13/15). A 15/15 technical success was achieved, but a 9/15 clinical success based on bilirubin decreased. Adverse events in 3/15 cases: bleeding, cholangitis and subhepatic fluid collection. Stent migrated in 3/15 cases. There was no re-stenosis; reintervention was necessary on 8/15. One patient died. EUS-PDD: anterograde drainage was decided due to chronic pancreatitis and recurrent choledocholithiasis in 3/5 and 2/5 cases, respectively. In 3/5 there was necessary cautery-assisted dilation. In 1/5 there was also necessary balloon dilation. Used stents included single and double pigtail, LAMS and self-expandable metal stent (SEMS). Technical and clinical success was achieved in 5/5, with no adverse events.

CONCLUSIONS: Anterograde EUS-BD and EUS-PDD for managing non-neoplastic obstructed biliary and pancreatic ducts are valuable alternatives when ERCP is not feasible. Reintervention after EUS-BD and EUS-PDD appears to be related to stent migration and re-stenosis, respectively.